Morphic Medical

GI Dynamics is Now Morphic Medical. Learn More.

Impact of Proximal Intestinal Exclusion with EndoBarrier on Key Metabolic Parameters and Cardiovascular Risk in the First NHS-UK EndoBarrier Service

In addition to reducing the requirement for insulin and a liver fat biomarker, EndoBarrier treatment reduced 10-year CVD risk by clinically useful amounts in patients with poorly controlled diabetes and obesity. These data suggest that EndoBarrier treatment in 100 patients could prevent between 8 and 9 events of CHD or stroke and save between 6 and 7 lives over the next 10 years, if effects were maintained.


How RESET Works

Maintenance of Efficacy After RESET

BBC News Item

DJBL for the Treatment of Type 2 Diabetes and Obesity: EASD 2022